BIOMATRIX™ FAMILY

Journal Papers [1-44]

1. **Mäkikallio, Timo et al.,** Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial The Lancet, Volume 388, Issue 10061, 2743-2752. Impact Factor 44·002. *http://www.sciencedirect.com/science/article/pii/S0140673616320670*

2. **Ng, Jaryl et al.** Over-expansion capacity and stent design model: An update with contemporary DES platforms International Journal of Cardiology, Volume 221, 171-179. Impact Factor 4.638 *http://www.internationaljournalofcardiology.com/article/S0167-5273(16)31105-6/pdf*

3. **Arnous S. et al.** Incidence and Mechanisms of Longitudinal Stent Deformation Associated with Biomatrix, Resolute, Element, and Xience Stents: Angiographic and Case-By-Case Review of 1,800 pcis. Catheterization and Cardiovascular Interventions; 2015. Impact Factor 2.514. *http://onlinelibrary.wiley.com/doi/10.1002/ccd.25790/full*

4. **Lee H.J. et al.** Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent in Patients with Acute Myocardial Infarction. International journal of cardiology 2015; 183:190–197. Impact Factor 5.509. *http://www.internationaljournalofcardiology.com/article/S0167-5273(15)00063-7/pdf*

5. **Puricel S. et al.** Comparison of Everolimus and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffolds. Journal of the American College of Cardiology 2015; 65(8):791– 801. Impact Factor 15.343. *http://content.onlinejacc.org/article.aspx?articleid=2130645" \l "tab1" http://content.onlinejacc.org/article.aspx?articleid=2130645#tab1*

6. **Raungaard B. et al.** Zotarolimus-Eluting Durable-polymer-Coated Stent Versus a Biolimus-Eluting Biodegradable-Polymer-Coated Stent in Unselected Patients Undergoing Percutaneous Coronary Intervention (SORT OUT VI): A Randomised Non-Inferiority Trial. The Lancet 2015; 385(9977):1527–1535. Impact Factor 39.06. *http://www.sciencedirect.com/science/article/pii/S0140673614617943*

7. **Tomai F. et al.** One-Year Outcome from an All-comers Population of Patients with ST-Segment Elevation Myocardial Infarction Treated with Biolimus-Eluting Stent with Biodegradable Polymer. Catheterization and Cardiovascular Interventions 2015; 85(3):352–358. Impact Factor 2.514. *http://onlinelibrary.wiley.com/doi/10.1002/ccd.25627/pdf*

8. **Urban P. et al.** Outcomes Following Implantation of the Biolimus A9-Eluting Biomatrix Coronary Stent: Primary Analysis of the e-Biomatrix Registry. Catheterization and Cardiovascular Interventions; 2015. Impact Factor 2.514. *http://onlinelibrary.wiley.com/doi/10.1002/ccd.25892/pdf*

9. **Cockburn J. et al.** Clinical Outcomes with 6 Months Dual Antiplatelet Therapy after Implantation of Biolimus-A9 Drug Eluting Coronary Stents. International journal of cardiology 2014; 172(1):185–189. Impact Factor 5.509. *http://www.sciencedirect.com/science/article/pii/S0167527314000278*

10. **Goyal B.K. et al.** A Two Year Analysis of Diabetic Subset e-Biomatrix Prospective, Multicentric, All-Comers Registry in India. Indian Heart Journal, 2014. *http://www.sciencedirect.com/science/article/pii/S0019483214002648*

11. **Young J.Y. et al.** Multicenter Randomized trial of 3-Month Cilostazol Use in Addition to Dual Antiplatelet Therapy after Biolimus-Eluting Stent Implantation for Long or Multivessel Coronary Artery Disease. American Heart Journal 2014; 167(2):241–248. Impact Factor 4.555. *http://www.sciencedirect.com/science/article/pii/S000287031300608X*

12. **Zhang Y.-J et al.** Biolimus-Eluting Stent with Biodegradable Polymer Improves Clinical Outcomes in Patients with Acute Myocardial Infarction. Heart, pages heartjnl - 2014. Impact Factor 6.023. *http://heart.bmj.com/content/101/4/271.short*

13. **Zhang Y.G. et al.** Biolimus-Eluting Stent with Biodegradable Polymer Improves Clinical Outcomes in Patients with Acute Myocardial Infarction. Heart 2014; published online.

14. **Raber L. et al.** Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction: Two-Year Clinical Results of the COMFORTABLE AMI Trial. Circ Cardiovasc Interv 2014; 7:355-364. Impact Factor 15.202. *http://circinterventions.ahajournals.org/content/7/3/355.long*

15. **Ormiston et al.** Stent Longitudinal Strength Assessed Using Point Compression: Insights from a Second-Generation, Clinically Related Bench Test. Circ Cardiovasc Interv 2014; 7:62-69. Impact Factor 15.202. *http://circinterventions.ahajournals.org/content/7/1/62.long*

16. **Saraf S. et al.** Procedural and Follow-up Outcomes Among Patients Undergoing Successful Recanalisation of Coronary Chronic Total Occlusions Using Biolimus Drug-Eluting Stents. Cardiovasc Interv Ther 2014. Impact Factor 2.536. *http://link.springer.com/article/10.1007/s12928-014-0243-y*

17. **Foin N. et al.** Maximal Expansion Capacity with Current DES Platforms: A Critical Factor for Stent Selection in the Treatment of Left Main Bifurcations? EuroIntervention 2013; 8:1315-1325. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/58th_issue/200/*

18. **Serruys P.W. et al.** Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Non-Inferiority Trial. JACC Cardiovasc Interv 2013; 6:777-789. Impact Factor 15.343. *http://interventions.onlinejacc.org/article.aspx?articleid=1730161*

19. **Park K.-H. et al.** The Impact of Triple Anti-Platelet Therapy for Endothelialization and Inflammatory Response at Overlapping Bioabsorbable Polymer Coated Drug-Eluting Stents in a Porcine Coronary Model. International Journal of Cardiology 2013; 168:1853-1858. Impact Factor 6.175. *http://www.internationaljournalofcardiology.com/article/S0167-5273(12)01699-3/fulltext*

20. **Raber L. et al.** Effect of Biolimus-Eluting Stents with Biodegradable Polymer vs. Bare-Metal Stents on Cardiovascular Events among Patients with Acute Myocardial Infarction: The COMFORTABLE AMI Randomized Trial. JAMA 2012; 308:777-787. Impact Factor: 30. *http://jama.jamanetwork.com/article.aspx?articleid=1352112*

21. **Raber L. et al. Co**mparison of Biolimus Eluted from an Erodible Stent Coating with Bare Metal Stents in Acute St-Elevation Myocardial Infarction (COMFORTABLE AMI Trial): Rationale and Design. EuroIntervention 2012; 7:1435-1443. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/login/?url_to=/eurointervention/ahead_of_print/201202-01/index.php?ind=1*

22. **Stefanini G.G. et al**. Biodegradable Polymer Drug-Eluting Stents Reduce the Risk of Stent Thrombosis at 4 Years in Patients Undergoing Percutaneous Coronary Intervention: A Pooled Analysis of Individual Patient Data from the ISAR-Test 3, ISAR-Test 4, and LEADERS Randomized Trials. Eur Heart J 2013; 33:1214- 1222. Impact Factor 14.72. *http://eurheartj.oxfordjournals.org/content/early/2012/03/22/eurheartj.ehs086.abstract*

23. **Grundeken M.J.D. & Wykrzykowska J.J.** Biolimus-Eluting Stent with Biodegradable Polymer: One Step Forward in the Fight against Stent Thrombosis Vulnerability? Interventional Cardiology 2012; 4:11-25. Impact Factor 15.343. *http://www.sciencedirect.com/science/article/pii/S1936879812000106*

24. **Stefanini G.G. et al.** Impact of Sex on Clinical and Angiographic Outcomes among Patients Undergoing Revascularization with Drug-Eluting Stents. JACC Cardiovasc Interv 2012; 5:301-310. 2/8 Durable Polymer.

25. **Stefanini G.G. et al.** Long-Term Clinical Outcomes of Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients with Coronary Artery Disease (LEADERS): 4 Year Follow-up of a Randomised Non-Inferiority Trial. The Lancet 2011; 378:1940-1948. Impact Factor 39.207. *http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961672-3/fulltext" \l "article_upsell" http://www.thelancet.com/journals/lancet/article/PIIS01406736%2811%2961672-3/fulltext#article_upsell*

26. **Wykrzykowska J. et al.** The Three Year Follow-up of the Randomised 'All-Comers' Trial of a Biodegradable Polymer Biolimus-Eluting Stent Versus Permanent Polymer Sirolimus-Eluting Stent (LEADERS). EuroIntervention 2011; 7:789-795. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/ahead_of_print/201110-01/*

27. **Gutierrez-Chico J.L. et al.** Long-Term Tissue Coverage of a Biodegradable Polylactide Polymer-Coated Biolimus-Eluting Stent: Comparative Sequential Assessment with Optical Coherence Tomography until Complete Resorption of the Polymer. Am Heart J 2011; 162:922-931. Impact Factor 6.023. *http://www.ahjonline.com/article/S0002-8703(11)00645-4/abstract*

28. **Klauss V. et al.** 2-Year Clinical Follow-up from the Randomized Comparison of Biolimus-Eluting Stents with Biodegradable Polymer and Sirolimus-Eluting Stents with Durable Polymer in Routine Clinical Practice. JACC Cardiovasc Interv 2011; 4:887-895. Impact Factor 15.343. *http://www.sciencedirect.com/science/article/pii/S1936879811004158*

29. **Wykrzykowska J. et al.** Implantation of the Biodegradable Polymer Biolimus Eluting Stent in Patients with High SYNTAX Score Is Associated with Decreased Cardiac Mortality Compared to a Permanent Polymer Sirolimus Eluting Stent: Two Year Follow-up Results from the 'All-Comers' LEADERS Trial. EuroIntervention 2011; 7:605-613. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/ahead_of_print/38_05/*

30. **Garg S. et al.** The Outcome of Bifurcation Lesion Stenting Using a Biolimus-Eluting Stent with a Bio-Degradable Polymer Compared to a Sirolimus-Eluting Stent with a Durable Polymer. EuroIntervention 2011; 6:928-935. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/34th_issue/*

31. **Steudel W. et al.** Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Novel Coronary Smooth Muscle Cell Proliferation Inhibitor Biolimus A9 in Healthy Individuals. J Clin Pharmacol 2011; 51:29-39. Impact Factor 7.39. *http://onlinelibrary.wiley.com/doi/10.1177/0091270010361255/abstract;jsessionid=07292320825034 6DC9217BEDB9B8DFD4.f01t04*

32. **Wykrzykowska J.J. et al.** Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the 'All-Comers' LEADERS Trial. Circ Cardiovasc Interv 2011; 4:47-56. Impact Factor 15.202. *http://circinterventions.ahajournals.org/content/4/1/47.long*

33. **Chia P.L. et al.** Biolimus-Eluting Biodegradable Polymer-Coated Stent Versus Bare Metal Stent in Acute in Acute ST-Elevation and Non ST-Elevation Myocardial Infarction: Justification for Biodegradable Polymer-Coated Stent in Acute Coronary Syndrome (JANICE) Registry. Acute Card Care 2011; 13:43-47. *http://informahealthcare.com/doi/pdf/10.3109/17482941.2011.553237*

34. **Ostojic M.C. et al.** The Pharmacokinetics of Biolimus A9 after Elution from the Biomatrix II Stent in Patients with Coronary Artery Disease: The STEALTH PK Study. Eur J Clin Pharmacol 2011;64:228. *http://informahealthcare.com/doi/pdf/10.3109/17482941.2011.553237*

35. **Wykrzykowska J.J. et al.** Value of the SYNTAX Score for Risk Assessment in the 'All-Comers' Population of the Randomized Multicenter LEADERS (Limus Eluted from a Durable Versus Erodable Stent Coating) Trial. J Am Coll Cardiol 2010; 56:272-277. Impact Factor 15.343. *http://www.ncbi.nlm.nih.gov/pubmed/20633818*

36. **Sarno G. et al. The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by** Percutaneous Coronary Intervention with Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). Am J Cardiol 2010; 105:475-479. Impact Factor 3.425. *http://www.ncbi.nlm.nih.gov/pubmed/20152241*

37. **Garg S. et al.** The Twelve-Month Outcomes of a Biolimus Eluting Stent with a Biodegradable Polymer Compared with a Sirolimus Eluting Stent with a Durable Polymer. EuroIntervention 2010; 6:233-239. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/28th_issue/*

38. **Barlis P. et al.** An Optical Coherence Tomography Study of a Biodegradable vs. Durable Polymer-Coated Limus-Eluting Stent: A LEADERS Trial Sub-Study. Eur Heart J 2010; 31:165-176. Impact Factor 14.273. *http://eurheartj.oxfordjournals.org/content/31/2/165.full.pdf+html*

39. **Schmidt W. et al.** A Comparison of the Mechanical Performance Characteristics of Seven Drug-Eluting Stent Systems. Catheter Cardiovasc Interv 2009; 73:350-360. Impact Factor 2.396. *http://www.ncbi.nlm.nih.gov/pubmed/19085917*

40. **Windecker S. et al.** Biolimus-Eluting Stent with Biodegradable Polymer Versus Sirolimus-Eluting Stent with Durable Polymer for Coronary Revascularisation (LEADERS): A Randomised Non-Inferiority Trial. The Lancet 2008; 372:1163-1173. Impact Factor. *39.207http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61244-1/fulltext*

41. **Grube E. & Buellesfeld L.** BioMatrix Biolimus A9-Eluting Coronary Stent: A Next-Generation Drug-Eluting Stent for Coronary Artery Disease. Expert Rev Med Devices 2006; 3:731-741. Impact Factor 1.784 *http://www.expert-reviews.com/doi/pdf/10.1586/17434440.3.6.731*

42. **Costa R.A. et al.** Angiographic Results of the First Human Experience with the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions. Am J Cardiol 2006; 98:443-446. Impact Factor 3.425. *http://www.ncbi.nlm.nih.gov/pubmed/16893694*

43. **Grube E. et al.** Six-Month Results of a Randomized Study to Evaluate Safety and Efficacy of a Biolimus A9 Eluting Stent with a Biodegradable Polymer Coating. EuroIntervention 2005; 1:53-57. Impact Factor 3.758. *http://www.pcronline.com/eurointervention/1st_issue/*

44. **Chan C. et al.** Acute and Long-Term Clinical and Angiographic Outcome after S-Stent Implantation: S-Stent Multicenter Safety and Efficacy Trial. Catheter Cardiovasc Interv 2004;62.459-444. Impact Factor 2.396. *http://www.ncbi.nlm.nih.gov/pubmed/15274151*

Selected Conference Papers [45-98]

45. **Windecker S.** Stent Design and Comprehensive Data Review: BioMatrix Biolimus-Eluting Stents. EuroPCR 2016.

46. **Kleber F.X.** The Impact of Comorbidities on Long–Term PCI Outcomes: Final Three Year Results from the Large, Multicenter e-BioMatrix Registry. TCT 2015.

47. **Roffi M.** Following Biolimus-Eluting Stenting, No Excess in 3 Year MACE in Diabetic Patients Not Treated with Insulin. TCT2015.

48. **Grundeken M.** Five-Year Clinical Follow-up after Treatment of Bifurcation Lesions with a Biodegradable Polymer-Coated Biolimus-eluting Stent or Durable Polymer-Coated Sirolimus-Eluting Stent: A Substudy of the LEADERS All-comers Randomised Trial. EuroPCR, 2015.

49. **Hildick-Smith D.** Long-Term Safety and Efficacy of Biolimus-Eluting Coronary Stents in an Unselected Patient Population: Final 3-Year Report of the Large, Multicenter e-Biomatrix. EuroPCR, 2015.

50. **Cook S.** EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease. TCT 2014.

51. **Windecker S.** Safety and Efficacy Profile of BioMatrix and Nobori in Simple and Complex Lesions. TCT 2014.

52. **Byrne R.A.** Pro Bioabsorbable Polymer-Based Metallic DES. TCT 2014.

53. **Granada J.F.** Bioabsorbable Polymer-Based Metallic DES: Technological and Biological Considerations. TCT 2014.

54. **Windecker S.** Bioresorbable Polymer-Based DES are the Right Choice to Minimize Stent Thrombosis! TCT 2014.

55. **Oldroyd K.** 2-year Outcomes and Angiograms from the Bifurcation Subgroup of the e-BioMatrix Registry. TCT 2014.

56. **Zhang Y.** Implantation of Biodegradable Polymer Biolimus-Eluting Stent in Patients with STEMI Is Associated with Decreased Cardiac Mortality and Major Adverse Cardiac Events (MACE) Compared to a Permanent Polymer Sirolimus-Eluting Stent: 5-Year Follow-up Results. EuroPCR 2014.

57. **Alhaddad I.** Stent Thrombosis, Bleeding and DAPT: Long-term Report from the Large Multi-Center e-BioMatrix Registry. EuroPCR 2014.

58. **Koh T.H.** Long-Term outcomes with Biolimus from BEACON II - Asia Population. AsiaPCR 2014.

59. **Oldroyd K.G.** Comparable Low Rates of MACE in Patients with STEMI and NSTEMI Treated with Biolimus-Eluting Stents. The e-BioMatrix registry. AsiaPCR 2014.

60. **Menown I.B.** Does the Existence of Primer Coating on Biolimus-Eluting Stents with Abluminal Biodegradable Polymer Influence Clinical Outcomes? Insights from the Large 'All-Comers' e-BioMatrix registry. AsiaPCR 2014.

61. **Windecker S.** Synthesis of Clinical Trials with the BioMatrix Stent Family. TCT 2013.

62. **Raungaard B. A** Prospective, Randomized, 'All-Comers' Trial of Biodegradable Polymer-Coated Biolimus-Eluting stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Stents: The SORT OUT VI Trial. TCT 2013

63. **Ahn J.** Comparison of Long Term Clinical Outcomes Between Bare Metal Stent Versus Different Types of Drug Eluting Stents for Treatment of Acute Myocardial Infarction. ESC 2013.

64. **Raber L.** Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare Metal Stents in Acute Myocardial Infarction: Two Year Clinical Follow-up and Results of Serial Multimodality Imaging (OCT/IVUS) - The COMFORTABLE AMI (clinical) - IBIS 4 (imaging) Trial. EuroPCR 2013.

65. **Urban P.** Cardiac Adverse Events, Stent Thrombosis, Bleeding and Dual Antiplatelet Therapy: First Report of the Primary Endpoint of the e-BioMatrix Registry. EuroPCR 2013.

66. **Eberli F. et al.** Comorbidities Determine Prognosis in Patients Undergoing Coronary Stenting: Results from Two Large Registries Evaluating Biolimus-A9-Eluting from Biodegradable Polymer Stents. EuroPCR 2013.

67. **Roffi M. et al.** Comparable Low 1-Year Cardiac Mortality Among Diabetic and Non-Diabetic Patients Undergoing Coronary Stenting with Biolimus-A9-Elution and Biodegradable Polymer. EuroPCR 2013.

68. **Serruys P.** Biolimus A9-Eluting Stents (BioMatrix). EuroPCR 2013.

69. **Linke A.** Five-year Clinical Outcomes of Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients with and without Diabetes Mellitus: a LEADERS Sub-study, Final report. AsiaPCR 2013.

70. **Walters D.** The BEACON II Registry: 4 Year Outcomes Asian Pacific Population. AsiaPCR 2013.

71. **Serruys P.** TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer: Final Report of the LEADERS study. TCT 2012.

72. **Raber L. et al.** Biolimus-Eluting Stents with Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction: The COMFORTABLE AMI Trial, EuroPCR 2012. Primary Endpoint of the Study.

73. **Serruys P.** GLOBAL LEADERS, Hot Line - From Late Breaking Trials to Clinical Practice Session. EuroPCR 2012. GLOBAL LEADERS Trial: Rationale and Design.

74. **Eberli F. et al.** Two-Year Clinical and Safety Outcomes of the e-BioMatrix PMS Registry. EuroPCR 2012.

75. **Santoso T.** BEACON II - a Prospective, Multi-Centre, Observational, Real-World Registry to Assess Clinical Outcomes of Patients after Treatment with the Biomatrix™ Stent – 3-Year Outcomes. AsiaPCR 2012.

76. **Ischinger T.** LEADERS Four-Year: A Prospective, Randomized Trial of a Bioabsorbable Polymer-Based Biolimus-Eluting Stent vs. a Durable Polymer-Based Sirolimus-Eluting Stent, Twilight sessions (Featured Clinical Research II). TCT 2011.

77. **Serruys P.** Lessons from BioMatrix and the LEADERS Trial at Four Years: Transitioning into the Global Program. TCT 2011.

78. **Wykrzykowska J.J. et al.** TCT-275. Three-Year Outcomes of Chronic Total Occlusion Treatment with Biolimus-Eluting Biodegradable Polymer Stent vs. Sirolimus-Eluting Permanent Polymer Stent In the LEADERS All-Comers Trial. TCT 2011.

79. **Costa R.** TCT-215. STEALTH I: Five-Year Follow-up from a Prospective, Randomized Study of Biolimus A9-Eluting Stent with a Biodegradable Polymer Coating vs. a Bare Metal Stent. TCT 2011.

80. **Urban P.** TCT-212. Are Results from an All-Comers Registry Comparable with the Results from 12-Month Results of the e-BioMatrix PMS Registry. TCT 2011.

81. **Stefanini G.** TCT-494. Impact of Renal Impairment on Clinical and Angiographic Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents: A Pooled Analysis of SIRTAX, LEADERS, and RESOLUTE All-Comers Trials. TCT 2011.

82. **Windecker S.** BioMatrix, Main Session: New Generation DES (ESC-EACTS Revascularisation Guidelines) - Head to Head Comparisons Focusing on Patient-Oriented Outcomes. EuroPCR 2011.

83. **Urban P.** e-BioMatrix PMS Registry - A Post Market Surveillance Registry for the BioMatrixTM DES. EuroPCR 2011. e-BioMatrix PMS 12-month Outcomes.

84. **Byrne R.** Biodegradable Polymer Versus Durable Polymer Drug-Eluting Stents for Patients with Coronary Artery Disease: 3 Years Pooled Analysis of Individual Patient Data from the Isar-Test 4, LEADERS and Isar-Test Randomised Trials. EuroPCR 2011.

85. **Koh T.H.** BioMatrix around the Globe - Asian Experience: How Does Registry Data Reflect Findings from Randomised Clinical Trials? AsiaPCR - Singapore, 2011. BEACON II 2-year Outcomes.

86. **Yazdani S.K. et al.** TCT-245: Endothelialization of Drug-Eluting Stents with Biodegradable Polymer Coating. J Am Coll Cardiol 2010; 56, B57.

87. **Serruys P. et al.** TCT-36: LEADERS: 3-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer Vs. Sirolimus-Eluting Stents with a Durable Polymer. J Am Coll Cardiol 2012; 56, B9.

88. **Wykrzykowska J.J. et al.** 'All-Comers' LEADERS Trial: Biolimus Eluting Stent Reduces Mortality in Patients with High SYNTAX Scores in the "All-Comers" LEADERS Trial. EuroPCR 2010.

89. **Klauss V.** LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer. TCT 2009.

90. **Garg S.** Does Stent Design Impact the Outcome in Bifurcation Treatment? EuroPCR 2009.

91. **Buszman P.** Outcomes with Drug-Eluting Stents in Acute Coronary Syndromes. EuroPCR 2009.

92. **Grube E.** et al. STEALTH I: Safety and Performance Evaluation of the Biosensors International's Biolimus A9 Drug Eluting Stent (BioMatrix). A 4 -Year Follow-Up. TCT 2008.

93. **Grube E.** Safety and Performance Evaluation of the Biosensors International's Biolimus A9 Drug Eluting Stent (BioMatrix). A 3-Year Safety Follow-Up. TCT 2007.

94. **Christians U. et al.** P1377: Safety, Tolerance and Pharmacokinetics of Biolimus A9 in Healthy Subjects in a Single Ascending Dose Study. European Heart Journal 2007; 28: 216.

95. **Christians U. et al.** P1382 : Safety of Biolimus A9 in a Double-Blinded, Placebo-Controlled Multiple Ascending Dose Trial. European Heart Journal 2007; 28:217.

96. **Missel E. et al.** Sustained Suppression of Neointimal Hyperplasia after Implantation of Biolimus A9-Eluting Stents: 12-Month Single-Center Angiographic and Three-Dimensional Intravascular Ultrasound Follow-Up. TCT 2006.

97. **Missel E. et al.** Late Intravascular Ultrasound Volumetric Analysis after Implantation of Sirolimus Versus Biolimus A9 Eluting Stents in Human Coronary Arteries. TCT 2005.

98. **Grube E. et al.** High Risk Subgroups in Patients Treated with the BioMatrix Biolimus A9-Eluting Coronary Stent: Results from the STEALTH (Stent Eluting A9 Biolimus Trial in Humans) Trial. TCT 2005.

Last updated: January 2017

BIOSENSORS INTERNATIONAL™

BIOSENSORS EUROPE SA

Rue de Lausanne 29
1110 Morges
Switzerland
Tel: +41 (0)21 804 80 00
Fax: +41 (0)21 804 80 01

BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD

36 Jalan Tukang
Singapore 619266
Tel: +65 6213 5777
Fax: +65 6213 5737